Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Key facts

Sponsor

Roswell Park Cancer Institute

Principal Investigator

Kunle Odunsi

Roswell Park Cancer Institute

Intervention

ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine(biological)

Enrollment

7 enrolled

Eligibility

18 years · FEMALE

Timeline

2012 – 2015

Study locations (1)

• Roswell Park Cancer Institute, Buffalo, New York, United States

Collaborators

National Cancer Institute (NCI) · Sanofi Pasteur, a Sanofi Company

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Malignant epithelial tumor of ovary

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06268665
  Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
  University of California, Davis
• RECRUITINGNANCT05937620
  Sentinel Node Detection With Technetium-99m Albumin Nanocolloid and ICG in Patients With Epithelial Ovarian Cancer
  Fundacion Clinic per a la Recerca Biomédica
• RECRUITINGNANCT06061874
  Ga68-FAPI-46 PET/CT for Preoperative Assessment of Peritoneal Carcinomatosis
  Jules Bordet Institute
• RECRUITINGNANCT05457595
  Clinical Study on the Re-irradiation of Lateral Pelvic Recurrences of Gynecological Malignancies
  CNAO National Center of Oncological Hadrontherapy
• ACTIVE NOT RECRUITINGPHASE3NCT01376752
  Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment
  UNICANCER

See all trials for Malignant epithelial tumor of ovary →